{"id":3771,"date":"2000-07-16T15:28:10","date_gmt":"2000-07-16T14:28:10","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=3771"},"modified":"2014-07-01T12:23:53","modified_gmt":"2014-07-01T12:23:53","slug":"4th-international-workshop-on-hiv-drug-resistance-treatment-strategies","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/3771","title":{"rendered":"4th International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain"},"content":{"rendered":"<p><strong>Reports by Paul Blanchard, Simon Collins and Polly Clayden, HIV i-Base.<\/strong><\/p>\n<p><strong>The 4th International Workshop on HIV Drug Resistance &amp; Treatment Strategies took place in Sitges, Spain, a resort town in Catalonia. This annual meeting has developed into one of the most important of the year for the presentation of developments in the field of drug resistance and treatment strategies. <\/strong><\/p>\n<p>Although many studies are small and findings preliminary they often form the basis of larger confirmatory trials. Innovative work from previous years has now become part of national and international treatment guidelines.<\/p>\n<p><a href=\"https:\/\/i-base.info\/htb\/keyword\/resistance-workshop-4th\">Reports from the workshop<\/a>.<\/p>\n<ul>\n<li><a title=\"Permanent link to Tenofovir (PMPA), defining cross-resistance profiles\" href=\"https:\/\/i-base.info\/htb\/3763\" rel=\"bookmark\">Tenofovir (PMPA), defining cross-resistance profiles<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing\" href=\"https:\/\/i-base.info\/htb\/3759\" rel=\"bookmark\">DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV\" href=\"https:\/\/i-base.info\/htb\/3753\" rel=\"bookmark\">Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Hydroxyurea is active in vitro against multidrug-resistant HIV\" href=\"https:\/\/i-base.info\/htb\/3751\" rel=\"bookmark\">Hydroxyurea is active in vitro against multidrug-resistant HIV<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to ABT-378\/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients\" href=\"https:\/\/i-base.info\/htb\/3745\" rel=\"bookmark\">ABT-378\/r (Lopinavir): defining a resistance profile and the effects of resistance on virological response in experienced patients<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Indinavir\/ritonavir at 400\/400 mg or 800\/100 mg as intensification\" href=\"https:\/\/i-base.info\/htb\/3743\" rel=\"bookmark\">Indinavir\/ritonavir at 400\/400 mg or 800\/100 mg as intensification<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Ritonavir\/saquinavir combination: effect of ritonavir dosage\" href=\"https:\/\/i-base.info\/htb\/3739\" rel=\"bookmark\">Ritonavir\/saquinavir combination: effect of ritonavir dosage<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to What is the significance of blips in viral load?\" href=\"https:\/\/i-base.info\/htb\/3737\" rel=\"bookmark\">What is the significance of blips in viral load?<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001\" href=\"https:\/\/i-base.info\/htb\/3731\" rel=\"bookmark\">Phenotypic resistance testing improves response to therapy: final analysis of VIRA3001<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to A prospective study of strategic treatment interruptions in patients with chronic HIV-infection\" href=\"https:\/\/i-base.info\/htb\/3727\" rel=\"bookmark\">A prospective study of strategic treatment interruptions in patients with chronic HIV-infection<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Added value of hydroxyurea or IL-2 to STIs remains uncertain\" href=\"https:\/\/i-base.info\/htb\/3722\" rel=\"bookmark\">Added value of hydroxyurea or IL-2 to STIs remains uncertain<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Continued benefits from protease inhibitor based therapy despite virological failure\" href=\"https:\/\/i-base.info\/htb\/3714\" rel=\"bookmark\">Continued benefits from protease inhibitor based therapy despite virological failure<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Do resistance mutations disappear off therapy?\" href=\"https:\/\/i-base.info\/htb\/3705\" rel=\"bookmark\">Do resistance mutations disappear off therapy?<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Selection of PI mutations during slow decay of VL and resistance after PI failure\" href=\"https:\/\/i-base.info\/htb\/3702\" rel=\"bookmark\">Selection of PI mutations during slow decay of VL and resistance after PI failure<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Thymidine analogues mutations (TAMS) and other NA-related resistance mutations\" href=\"https:\/\/i-base.info\/htb\/3698\" rel=\"bookmark\">Thymidine analogues mutations (TAMS) and other NA-related resistance mutations<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to Nevirapine vs efavirenz: the SENC trial\" href=\"https:\/\/i-base.info\/htb\/3694\" rel=\"bookmark\">Nevirapine vs efavirenz: the SENC trial<\/a><\/li>\n<\/ul>\n<ul>\n<li><a title=\"Permanent link to A warning on simplification strategies: not suitable for all\" href=\"https:\/\/i-base.info\/htb\/3692\" rel=\"bookmark\">A warning on simplification strategies: not suitable for all<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Reports by Paul Blanchard, Simon Collins and Polly Clayden, HIV i-Base. The 4th International Workshop on HIV Drug Resistance &amp; Treatment Strategies took place in Sitges, Spain, a resort town in Catalonia. This annual meeting has developed into one of &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[12,116],"class_list":["post-3771","post","type-post","status-publish","format-standard","hentry","category-conference-reports","tag-conference-index","tag-idrw-4th-2000"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=3771"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3771\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=3771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=3771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=3771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}